RIO DE JANEIRO, BRAZIL - The covid-19 pandemic has exposed a weakness in Brazil: the high dependence on imported raw materials from China for vaccine production and the scrapping of laboratories and factories used to produce immunizers in the country.
While in the 1980s Brazil had at least five institutes capable of producing vaccines, today there are only two in operation: Bio-Manguinhos, of Fiocruz, and the Butantan Institute.
And of the 17 vaccines currently distributed by these two research institutes, only four are manufactured entirely in Brazil and do not depend on the import of the Active Pharmaceutical Ingredient . . .